Clinical Trial Update: An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma [Phase 1]

View source ↗

Summary

An open-label Phase I study evaluating a Super CAR-T therapy targeting GPC3 in advanced hepatocellular carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Super CAR-T (CAR-T cell therapy targeting glypican-3 (GPC3))

Snippet

Sponsor: Guangzhou FineImmune Biotechnology Co., LTD. | Conditions: Advanced Hepatocellular Carcinoma (HCC), GPC3 Positive Hepatocellular Carcinoma | Phase 1 | Status: RECRUITING